Recent Updates
Recently added Catalysts

pirtobrutinib combined with epcoritamab

Phase 2

CLL / SLL | Small molecule | Other |Eli Lilly and Company|Trials Updated: Oct 6, 2026

Development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment70

FDA Designations

No designations recorded

Clinical trial landscape

pirtobrutinib combined with epcoritamab · 1 trial · 1 indication

Phase 2 1
NCT07860775Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.CLL / SLL
NOT YET_RECRUITING70 Analytics
PHASE2NOT YET_RECRUITING
Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.
CLL / SLL
NCT0786077570
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate efficacy in terms of Progression-free survival (PFS)
24 months after first dose of pirtobrutinib.

To evaluate efficacy in terms of Progression-free survival (PFS) at 24 months after first dose of pirtobrutinib.

Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Pirtobrutinib combined with epcoritamabEXPERIMENTALPirtobrutinib combined with epcoritamab

Interventions

NameTypeDescription
pirtobrutinib combined with epcoritamabCOMBINATION_PRODUCTcombination treatment
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites17

In order to be eligible to participate in this study, a patient must meet all of the following criteria: * Documented relapsed or refractory CLL or SLL (SLL in Cohort Expansion only) following at least one systemic 1st-line treatment * Requiring treatment according to International Workshop on Chro...

Countries:DenmarkNetherlandsSweden
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 6, 2026NCT07860775NEW_TRIAL: changed
LOWOct 6, 2026NCT07860775NEW_TRIAL: changed

Explore more on BiopharmaWatch

Eli Lilly and Company (LLY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with PCompanies A to ZEvery biotech and pharma company we track